Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Fineline Cube Apr 7, 2026
Company Deals

Sansure Biotech to Acquire WWHS Biotech, Gaining Exclusive Infrared Fluorescence Platform for Full-Scenario IVD Expansion

Fineline Cube Apr 7, 2026
Company Deals

Conmind Medical Raises $29M in Series C to Advance Brain-Computer Interface and Cardio-Cerebral Integrated Care Platform

Fineline Cube Apr 7, 2026
Company Deals Legal / IP

Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software

Fineline Cube Apr 4, 2026
Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Fineline Cube Apr 4, 2026
Policy / Regulatory

China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized

Fineline Cube Apr 7, 2026
Company Drug

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Fineline Cube Apr 7, 2026
Company Drug

Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer

Fineline Cube Apr 7, 2026
Company Drug

Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial

Fineline Cube Sep 6, 2024

Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from...

Company Deals

Voyager Therapeutics Secures Licensing Deal with Novartis for Gene Therapy Capsid

Fineline Cube Sep 6, 2024

Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with...

Company Medical Device

Fujirebio’s HBsAg Detection Kit Receives NMPA Approval, Enhances Early Diagnosis Capabilities

Fineline Cube Sep 6, 2024

Fujirebio Inc., a leading diagnostic company based in Japan, has received approval from China’s National...

Company Drug

Jiangsu Kanion Pharmaceutical Gets NMPA Go-Ahead for Psoriasis Drug Clinical Trial

Fineline Cube Sep 6, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a prominent pharmaceutical company based in China, has...

Company Medical Device

Genesis MedTech Secures NMPA Approval for Innovative Surgical Energy Products

Fineline Cube Sep 6, 2024

Genesis MedTech, a leading medical device company headquartered in Singapore, has secured marketing approvals from...

Company Medical Device

True Health’s Advanced Microwave Ablation System Gains NMPA Nod for Liver Tumor Treatment

Fineline Cube Sep 6, 2024

True Health (Guangdong Hengqin) Medical Technology Co., Ltd has received marketing approval from China’s National...

Company Medical Device

Venus Medtech Initiates Global Study with Venus Vitae TAVR System Implantations

Fineline Cube Sep 6, 2024

Venus Medtech (Hangzhou) Inc., listed on the Hong Kong Stock Exchange as HKG: 2500, has...

Policy / Regulatory

China’s Hainan Free Trade Port Implements ‘Zero Tax’ on Medical Imports for Designated Entities

Fineline Cube Sep 6, 2024

In a joint effort to bolster healthcare services, China’s Ministry of Finance, National Health Commission...

Company Drug

Viatris Launches First-of-Its-Kind Nasal Spray Dymista in China for Allergic Rhinitis

Fineline Cube Sep 6, 2024

Viatris Inc. (NASDAQ: VTRS), a leading global pharmaceutical company based in the U.S., has announced...

Company Medical Device

Sansure Biotech Wins NMPA Nod for ALDH2 Gene Polymorphism Detection Kit

Fineline Cube Sep 5, 2024

Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...

Company Drug

Novo Nordisk Advances in China with Submission of Sogroya for Adult Growth Hormone Deficiency

Fineline Cube Sep 5, 2024

Denmark’s pharmaceutical heavyweight, Novo Nordisk (NYSE: NVO), has reached a significant milestone with the National...

Company

AstraZeneca China Restructures Biopharma Unit to Boost Chronic Disease Management

Fineline Cube Sep 5, 2024

AstraZeneca (NASDAQ: AZN)’s Chinese subsidiary has announced a strategic restructuring of its China biopharmaceutical business...

Company Drug

Kelun-Biotech’s ADC for Cancer Gets NMPA Review, Expands MSD Collaboration

Fineline Cube Sep 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has achieved a regulatory milestone with its clinical...

Company Deals R&D

Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments

Fineline Cube Sep 5, 2024

Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...

Company Drug

Roche’s Columvi for Relapsed DLBCL Gets Review Nod from China’s CDE for New Indication

Fineline Cube Sep 5, 2024

The Center for Drug Evaluation (CDE) in China has accepted for review an additional indication...

Company Drug

Jiangsu Hengrui’s Ivarmacitinib for Adult Alopecia Areata Accepted for Review by China’s CDE

Fineline Cube Sep 5, 2024

The Center for Drug Evaluation (CDE) has given the green light for the review of...

Policy / Regulatory R&D

US Allows Science and Technology Agreement with China to Expire, Pointing to Deepening R&D Competition

Fineline Cube Sep 5, 2024

The US-China Science and Technology Agreement (STA), a pivotal accord initially inked in 1979 by...

Company

Novartis Builds Two Radioligand Therapy Facilities in U.S. to Expand Cancer Treatment Capabilities

Fineline Cube Sep 5, 2024

Novartis AG (NYSE: NVS), a Swiss pharmaceutical giant listed on the NYSE under the ticker...

Deals

Jiangsu Suzhou Launches $843 Million Biomedicine Fund to Boost Pharma and Medical Device Innovation

Fineline Cube Sep 5, 2024

The Jiangsu Suzhou Biomedicine Industry Special Fund of Fund (FoF), a colossal pharmaceutical investment vehicle...

Company Deals

Sage Group Expands into China’s Healthcare Market with Cenponts Healthcare Partnership

Fineline Cube Sep 5, 2024

Sage Group, a UK-based financial advisory powerhouse, has announced a strategic foray into China’s burgeoning...

Posts pagination

1 … 282 283 284 … 646

Recent updates

  • Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention
  • Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer
  • Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response
  • China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized
  • Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Company Drug

Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer

Company Drug

Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response

Policy / Regulatory

China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.